Inogen
INGN
208 hedge funds and large institutions have $2.03B invested in Inogen in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 78 reducing their positions, and 17 closing their positions.
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
6% more funds holding
Funds holding: 197 → 208 (+11)
1% more capital invested
Capital invested by funds: $2.01B → $2.03B (+$22.4M)
0.73% more ownership
Funds ownership: 102.45% → 103.18% (+0.73%)
7% less call options, than puts
Call options by funds: $5.17M | Put options by funds: $5.55M
9% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 78
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$23.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$7.94M |
| 4 |
BlackRock
New York
|
+$6.58M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.45M |
Top Sellers
INGN Hedge Fund Activity: Q3 2017 in Review
208 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Inogen (INGN) for Q3 2017, worth a combined $2.03B — up 1.1% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new INGN positions and 17 closed out — a net gain of 14 holders — while 71 added to existing stakes and 78 trimmed.
The largest buyer was Vanguard Group, adding an estimated $24.1M. The largest seller was Marshall Wace North America, cutting an estimated $13.5M.
- 208 institutional investors held Inogen (INGN) as of Q3 2017, up from 197 in Q2 2017.
- Funds reported $2.03B of Inogen stock for Q3 2017, up 1.1% quarter-over-quarter.
- 31 funds opened new Inogen positions in Q3 2017 and 17 closed out, a net change of +14 holders.
- The largest Inogen buyer in Q3 2017 was Vanguard Group, an estimated $24.1M added.
- The largest Inogen seller in Q3 2017 was Marshall Wace North America, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2017.